The company was testing its therapy, cibotercept, in patients with pulmonary arterial hypertension (PAH) - a rare disease ...

Whether you’re a senior in high school or a senior-living resident, you’ve likely heard of Viagra (sildenafil) — the original ...

A month after halting dosing in two of the three treatment arms of a phase 2 trial of its pulmonary arterial hypertension ...

Shares in Keros Therapeutics fell sharply Wednesday morning after it said it halted trials of its treatment for pulmonary hypertension after finding adverse health effects in patients trialing the ...

Keros Therapeutics has halted the dosing of its treatment for pulmonary hypertension due to adverse health effects discovered during trials. The clinical-stage biopharmaceutical company said Wednesday ...

NEW YORK, NY / ACCESS Newswire / January 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros ...

The action affects the TROPOS trial of cibotacept (KER-012), an activin signalling inhibitor that works in a similar way to ...

Safety of a Potential New Treatment to Manage Complications from Sickle Cell Disease Apr. 11, 2024 — A drug approved to treat pulmonary arterial hypertension may be effective at managing ...

Erri, S. and Oroszi, T. (2025) Isolated Systolic Hypertension in Geriatrics. International Journal of Clinical Medicine, 16, ...

Last Friday saw the USA’s Center for Medicare and Medicaid Services (CMS) announce the selection of 15 new drugs covered ...

LEXINGTON, Mass., Jan. 15, 2025 (GLOBE NEWSWIRE) -- (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage ...

Keros Therapeutics (KROS) announced that it has voluntarily halted all dosing in the TROPOS trial, a Phase 2 clinical trial of cibotercept in ...